Ironwood Pharmaceuticals, Inc. (IRWD)
3.77
+0.17
(+4.72%)
USD |
NASDAQ |
Oct 15, 16:00
3.77
0.00 (0.00%)
After-Hours: 04:10
Ironwood Pharmaceuticals Research and Development Expense (Quarterly) : 21.96M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.96M |
| March 31, 2026 | 21.50M |
| December 31, 2025 | 21.40M |
| September 30, 2025 | 21.99M |
| June 30, 2025 | 22.91M |
| March 31, 2025 | 26.95M |
| December 31, 2024 | 24.91M |
| September 30, 2024 | 29.32M |
| June 30, 2024 | 29.88M |
| March 31, 2024 | 25.30M |
| December 31, 2023 | 35.06M |
| September 30, 2023 | 32.28M |
| June 30, 2023 | 34.31M |
| March 31, 2023 | 12.56M |
| December 31, 2022 | 10.11M |
| September 30, 2022 | 11.18M |
| June 30, 2022 | 11.09M |
| March 31, 2022 | 10.47M |
| December 31, 2021 | 31.49M |
| September 30, 2021 | 10.55M |
| June 30, 2021 | 11.77M |
| March 31, 2021 | 15.07M |
| December 31, 2020 | 15.85M |
| September 30, 2020 | 19.87M |
| June 30, 2020 | 21.44M |
| Date | Value |
|---|---|
| March 31, 2020 | 27.34M |
| December 31, 2019 | 25.67M |
| September 30, 2019 | 24.38M |
| June 30, 2019 | 28.76M |
| March 31, 2019 | 31.51M |
| December 31, 2018 | 27.54M |
| September 30, 2018 | 28.18M |
| June 30, 2018 | 23.19M |
| March 31, 2018 | 36.50M |
| December 31, 2017 | 40.12M |
| September 30, 2017 | 37.06M |
| June 30, 2017 | 37.34M |
| March 31, 2017 | 33.70M |
| December 31, 2016 | 35.68M |
| September 30, 2016 | 37.53M |
| June 30, 2016 | 31.68M |
| March 31, 2016 | 31.84M |
| December 31, 2015 | 27.63M |
| September 30, 2015 | 25.83M |
| June 30, 2015 | 28.65M |
| March 31, 2015 | 26.64M |
| December 31, 2014 | 27.48M |
| September 30, 2014 | 25.12M |
| June 30, 2014 | 22.14M |
| March 31, 2014 | 24.01M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie, Inc. | 2.344B |
| Xencor, Inc. | 71.90M |
| Viking Therapeutics, Inc. | 115.75M |
| IDEAYA Biosciences, Inc. | 108.69M |
| BioMarin Pharmaceutical, Inc. | 206.95M |